Skip to main content

Current Trends in Monoclonal Antibody Development and Manufacturing

  • Book
  • © 2010

Overview

  • Monoclonal antibodies represent one of the fastest growing areas of new drug development within the pharmaceutical industry and monoclonal antibodies products will become increasingly prevalent over the next decade
  • Provides an understanding of what is currently being done in the industry to develop, manufacture, and release monoclonal antibody products and what will be required for a successful regulatory submission
  • Includes supplementary material: sn.pub/extras

Part of the book series: Biotechnology: Pharmaceutical Aspects (PHARMASP, volume XI)

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 229.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (19 chapters)

  1. Design Of Therapeutic MABS

  2. Recovery and Purification

  3. Formulation and Delivery

  4. Analytics and Specification Setting for MABS

Keywords

About this book

Monoclonal antibodies represent one of the fastest growing areas of new drug development within the pharmaceutical industry. Several blockbuster products have been approved over the past several years including Rituxan, Remicade, Avastin, Humira, and Herceptin. In addition, over 300 new drugs are currently in clinical trials. With both large, established biotechnology companies and small start-ups involved in the development of this important class of molecules, monoclonal antibodies products will become increasingly prevalent over the next decade.

Recently the regulatory review of monoclonal antibodies has been moved from Center for Biologics and Research to the Center for Drug Evaluation and Research (CDER) division of the US Food and Drug Administration. It is anticipated that CDER will expect a certain minimal amount of data to be provided as more of these products move through the regulatory pipeline. Current Trends in Monoclonal Antibody Development and Manufacturing will provide readers with an understanding of what is currently being done in the industry to develop, manufacture, and release monoclonal antibody products and what will be required for a successful regulatory submission.

Editors and Affiliations

  • Genentech Inc., San Francisco, U.S.A.

    Steven J. Shire

  • Omeros Corporation, Seattle, U.S.A.

    Wayne Gombotz

  • Boehringer Ingelheim Pharma KG, Biberach, Germany

    Karoline Bechtold-Peters

  • Genentech, Inc., South San Francisco, U.S.A.

    James Andya

Bibliographic Information

  • Book Title: Current Trends in Monoclonal Antibody Development and Manufacturing

  • Editors: Steven J. Shire, Wayne Gombotz, Karoline Bechtold-Peters, James Andya

  • Series Title: Biotechnology: Pharmaceutical Aspects

  • DOI: https://doi.org/10.1007/978-0-387-76643-0

  • Publisher: Springer New York, NY

  • eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)

  • Copyright Information: Springer-Verlag New York 2010

  • Hardcover ISBN: 978-0-387-76642-3Published: 12 November 2009

  • Softcover ISBN: 978-1-4614-2491-8Published: 25 February 2012

  • eBook ISBN: 978-0-387-76643-0Published: 11 November 2009

  • Edition Number: 1

  • Number of Pages: XIV, 354

  • Topics: Neurosciences, Pharmacology/Toxicology

Publish with us